Henlez, a Danish startup advancing treatments for chronic dermatological condition hidradenitis suppurativa, raised $1m in Seed funding.
Karolinska Development (Nasdaq Stockholm: KDEV) and Eir Ventures participated in the round investing each $500k.
The company intends to use the funds for the further development of its topical HEN-001 to facilitate a forthcoming clinical evaluation of the product as well as an expansion of the patent portfolio.
Founded 2019 by former Novozymes A/S scientist and current CEO Jeppe Mouritsen, Henlez is advancing a pre-clinical development program called HEN-001, an enzyme-based, topical application directed towards hidradenitis suppurativa – a highly stigmatizing and chronic inflammatory condition characterized by severe pain, malodorous drainage and permanent scarring of the armpits and groin.
FinSMEs
25/10/2022